L3VLUP
ProSign in

REGN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

REGNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • REGN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterREGNJNJ
Q3 202024 holders, $17.4bn30 holders, $26.2bn
Q4 202026 holders, $15.2bn32 holders, $26.6bn
Q1 202122 holders, $13.7bn31 holders, $25.3bn
Q2 202127 holders, $15.3bn37 holders, $25.6bn
Q3 202126 holders, $15.5bn40 holders, $24.1bn
Q4 202128 holders, $16.3bn33 holders, $25.2bn
Q1 202225 holders, $19.2bn35 holders, $28.2bn
Q2 202226 holders, $16.5bn33 holders, $26.9bn
Q3 202224 holders, $19.0bn36 holders, $25.4bn
Q4 202230 holders, $20.2bn35 holders, $27.6bn
Q1 202332 holders, $22.3bn42 holders, $24.5bn
Q2 202328 holders, $18.8bn38 holders, $25.0bn
Q3 202326 holders, $21.1bn37 holders, $18.9bn
Q4 202335 holders, $21.9bn31 holders, $19.0bn
Q1 202428 holders, $23.6bn32 holders, $19.7bn
Q2 202428 holders, $25.6bn35 holders, $20.4bn
Q3 202431 holders, $25.0bn28 holders, $22.3bn
Q4 202427 holders, $13.8bn37 holders, $20.4bn
Q1 202529 holders, $12.2bn32 holders, $20.5bn
Q2 202532 holders, $9.3bn31 holders, $18.4bn
Q3 202533 holders, $10.1bn32 holders, $23.7bn
Q4 202533 holders, $16.3bn29 holders, $27.8bn
Q1 202624 holders, $15.2bn34 holders, $35.6bn
Q2 202622 holders, $10.6bn33 holders, $39.1bn
REGN

Regeneron Pharmaceuticals

Holders
32
Reported value
$9.3bn
Buyers
24
Sellers
10

Breadth +14 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only REGN (12)

ARK Investment Management LLC, Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, Freestone Grove Partners LP, Hudson Bay Capital Management LP, Scion Asset Management LLC, Southeastern Asset Management Inc, Squarepoint Ops LLC, Tudor Investment Corp, Voloridge Investment Management LLC, Walleye Capital LLC

Only JNJ (11)

Arrowstreet Capital LP, Brevan Howard Capital Management LP, Caxton Associates LLP, GAMCO Investors Inc, Janus Henderson Group Ltd, Markel Group Inc, MFS Investment Management, Quantbot Technologies LP, Renaissance Technologies LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →